Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
Key Highlights
- ➤ZORYVE cream 0.15% wins Marie Claire’s inaugural Best Prescription Skin Solution Award
- ➤ZORYVE becomes first prescription medication to receive the Marie Claire award
- ➤ZORYVE ranks number one prescribed branded topical therapy across three inflammatory dermatoses
- ➤ZORYVE treats mild to moderate atopic dermatitis in adults and children 6 years and older
Expert Statements
Mona Shahriari, MD, Associate Clinical Professor of Dermatology at Yale School of Medicine and Associate Director of Clinical Trials at CCD Research
“The launch of Marie Claire’s Best Prescription Skin Solution Award recognizes something important: innovation in skincare doesn’t stop at the beauty counter. Prescription therapies can fundamentally change the experience of living with a chronic inflammatory skin disease, and that impact should not be understated.”
Mona Shahriari, MD, Associate Clinical Professor of Dermatology at Yale School of Medicine and Associate Director of Clinical Trials at CCD Research
“As the inaugural recipient, ZORYVE exemplifies the kind of innovation this new category was created to recognize. ZORYVE is a non-steroidal treatment option that helps individuals with eczema achieve clearer skin and itch relief, with a formulation designed with the skin barrier in mind and without ingredients known to compromise it. That matters, because in eczema, restoring and protecting the skin barrier isn’t secondary to treatment — it’s central to it.”
Frank Watanabe, President and Chief Executive Officer of Arcutis
“We are proud that ZORYVE cream 0.15% for eczema has been named the winner of Marie Claire’s Best Prescription Skin Solution Award.”
Frank Watanabe, President and Chief Executive Officer of Arcutis
“This new category, dedicated specifically to prescription skin solutions, is recognition of the innovation happening in medical dermatology, and being selected as its first recipient is an incredible honor.”
Frank Watanabe, President and Chief Executive Officer of Arcutis
“ZORYVE was developed to address the most complex and persistent challenges faced by people living with chronic inflammatory skin diseases, and this award is recognition of our commitment to developing advanced targeted topical therapies that help individuals with these conditions, including eczema.”
* Newly created award category highlights innovation in prescription skin treatment * ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award * ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE(®) (roflumilast) cream 0.15% was presented with the 2026 “Best Prescription Skin Solution” Award by Marie Claire magazine. The magazine created this award category as part of its Marie Claire US Beauty Awards to recognize medical innovation in bringing advanced skin solutions to consumers. ZORYVE is the first prescription medication to win this award and is being recognized for the innovation it offers to people with mild to moderate atopic dermatitis (eczema) 6 years of age and older.
Get started
Create a free account to read the full story.